



# KICK-OFF MEETING

1<sup>st</sup>-3<sup>rd</sup> October 2013

Kennedy Institute Of Rheumatology, Roosevelt Drive, Headington - Oxford, OX3 7FY - UK

## DAY 1 - TUESDAY, 1<sup>st</sup> OCTOBER - KENNEDY INSTITUTE - SEMINAR ROOM

Arrival of Athero-Flux guests at Kennedy Institute Of Rheumatology, Roosevelt Drive, Headington Oxford, OX3 7FY

12.30-14.00 Lunch in Kennedy Institute Seminar room and Kennedy tour

### SME-LED SYMPOSIUM WITH PARTNERS

14.00-15.00 Henrik Örum & Marie Wickström Lindholm - Santaris Pharma A/S - Denmark

15.00-16.00 Reijo Laaksonen & Kim Ekroos - Zora Biosciences OY - Finland

16.00-16.30 *Coffee break*

16.30 Seminar Tony Futerman – Weizmann (for the whole Kennedy)  
“Why are there so many sphingolipid species and what do they all do?”

Transport to Trinity College (Broad St, Oxford OX1 3BH)

**Communal dinner at Trinity**

## DAY 2 - WEDNESDAY, 2<sup>nd</sup> OCTOBER - TRINITY COLLEGE - SUTRO ROOM

07.30-09.00 *Breakfast*

09.00-09.30 Coordinator address Marc Feldmann - University of Oxford - UK

09.30-10.30 Joanna Frost - Reporting and Finance - University of Oxford - UK

10.30-11.00 *Coffee break*

### WP-LEADER LED SYMPOSIUM (INTRODUCED AND CHAIRED BY EACH WP LEADER)

11.00-11.50 **WP1 Discovery of key regulatory nodes within SL biosynthesis in patients with coronary artery diseases via Flux methodologies**  
Reijo Laaksonen & Kim Ekroos - Zora Biosciences OY - Finland (WP leader) (20 mins)  
Katriina Aalto-Setälä - University of Tampere - Finland (15 mins)  
Discussion (15 mins)

11.50-12.40 **WP2 Genome-scale RNAi screening to reveal rate-limiting pathways in ceramide metabolism and signalling**  
Birte Sönnichsen - Cenix BioScience GmbH - Germany (WP leader) (20 mins)  
Ejsing Christer – Syddansk Universitet - Denmark (15 mins)  
Discussion (15 mins)

Kennedy Institute Of Rheumatology, Roosevelt Drive, Headington - Oxford, OX3 7FY - UK

12.40-14.00 *Lunch*

14.00-14.50 **WP3 Evaluation of the significance of prospective therapeutic targets within the SL pathway in terms of inflammatory signalling**

Zhong-Qun Yan - Karolinska Institutet - Sweden (WP leader) (20 mins)

Tony Futerman - Weizmann Institute of Science - Israel (15 mins)

Discussion (15 mins)

14.50-15.40 **WP4 Evaluation of biodistribution, bioactivity and pro-atherogenic properties of alterations in SL metabolism**

Evangelos Andreakos - Biomedical Research Foundation Academy Of Athens - Greece (WP leader) (20 mins)

Giulia Nigro - Institut Pasteur - France (15 mins)

Discussion (15 mins)

15.40-16.10 *Coffee break*

16.10-17.00 **WP5 Development of LNA oligonucleotide-based therapeutics targeting SL metabolism and its associated signalling**

Henrik Örum & Marie Wickström Lindholm - Santaris Pharma A/S - Denmark (WP leader) (20 mins)

Jennifer Cole - University of Oxford - UK (15 mins)

Discussion (15 mins)

17.00-17.20 **WP6 Management, Review and Assessment**

**WP7 Dissemination and Diffusion of project results**

Paola Cesaroni - ALTA Ricerca e Sviluppo in Biotecnologie Srlu (20 mins)

Communal dinner at Trinity

## DAY 3 - THURSDAY, 3<sup>rd</sup> OCTOBER

07.30-09.00 *Breakfast*

Departures